Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: StocksDATsoar who wrote (57857)	8/3/2000 11:26:24 AM
From: Buckey	Read Replies (1) \| Respond to of 150070

HIVC may be back in play zamnet.zm News Canadian company to try its AIDS drug in Zambia By Bwalya Mubanga A Canadian HIV/AIDS based company, HIV- VAC Inc. has chosen Zambia to try its Anti Retro Viral Drugs. HIV - VAC's Zambian representative Dr. Nehe Nwankwo yesterday said the company which has its liason office in Ndola is awaiting a response from the Zambian government through the National HIV/AIDS/Vaccine working group. Dr. Nwankwo, who until recently was in the United States, said if approved the drugs will bring down the levels of HIV/AIDS infections. The vaccine which was originally discovered by Professor Skinner of Birmingham University in the United Kingdom was meant for trials before any nation could approve it. He said the Anti Retro Viral Drugs which is already on trials in Russia has three phases. Dr Nwankwo explained that the vaccine should be first tested for its safety, then its efficacy and finally if it can really prevent the HIV/AIDS infection. He said for the whole programme to succeed, there was need for educating the public on the benefits, risks and ethical issues concerning the vaccine and those on trial. Dr Nwankwo assured the nation that if approved, the vaccine will be free and those on trial will be supported fully until the vaccine is approved. He said another drug which reduces the viral load in the HIV infected human body is already on the market. Dr Nwankwo said the medicine which costs about K3 million for a monthly dosage was just too expensive for an average Zambian. He said the medicine was very effective in that despite being positive, patients tend to lead normal lives if they take the medicine under the guidance of a qualified medical doctor. -------------------------------------------------------------------------------- The Post / Post Newspapers / post@zamnet.zm --------------------------------------------------------------------------------